Drucker Wealth 3.0 LLC Trims Stock Position in Pfizer Inc. $PFE

Drucker Wealth 3.0 LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 18.6% during the second quarter, Holdings Channel reports. The firm owned 67,503 shares of the biopharmaceutical company’s stock after selling 15,443 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Pfizer were worth $1,725,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PFE. Pacer Advisors Inc. lifted its position in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi lifted its position in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the period. Nuveen LLC purchased a new position in Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. lifted its position in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after buying an additional 9,041,990 shares during the period. Finally, Vanguard Group Inc. lifted its position in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on PFE shares. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Finally, UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Price Performance

NYSE PFE opened at $24.81 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82. The stock has a 50-day moving average of $24.86 and a 200 day moving average of $24.14. The company has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.83 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the company earned $0.60 EPS. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.